All In Biotech

Drug Trial Radar · NCT05957107

Phase II Trial of VDJ001 in Patients With Moderate-to-severe Active Rheumatoid Arthritis

Randomized, Double-blind, Placebo, Positive-controlled Phase II Trial of VDJ001 in Patients With Moderate-to-severe Active Rheumatoid Arthritis

Last checked: Nov 20, 2026Latest source record: Jul 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 181 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

181

Actual

Start

May 26, 2022

Primary completion

Jun 2, 2023

Study completion Jun 2, 2023

Sponsor

Lead sponsor
Beijing VDJBio Co., LTD.Industry
Sponsor type
Industry
First posted
Jul 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo and tocilizumab controlled phase II trial in RA patients to evaluate the initial efficacy, safety, pharmacokinetic, pharmacodynamic characteristics, and immunogenicity of VDJ001 in RA patients.

Conditions

  • Rheumatoid Arthritis

Interventions

  • Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody InjectionBiological

    The drug was administered once every 4 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients who achieved ACR20 at week 12.Time frame: 12 weeks

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Baoji Central Hospital

    Baoji, China

  • Beijing Hospital

    Beijing, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, China

  • Chenzhou First People's Hospital

    Chenzhou, China

  • Pingxiang People's Hospital

    Jiangxi, China

  • Jilin Province People's Hospital

    Jilin City, China

  • Affiliated Hospital of North Sichuan Medical College

    Nanchong, China

  • Drum Tower Hospital Affiliated to Nanjing University Medical School

    Nanjing, China

  • Puyang Oilfield General Hospital

    Pujiang, China

  • Qilu Hospital of Shandong University

    Shandong, China

  • Peking University Shenzhen Hospital

    Shenzhen, China

  • People's Hospital of Xinjiang Uygur Autonomous Region

    Xinjiang, China

  • Zaozhuang Municipal Hospital

    Zaozhuang, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, China

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.